Mochi Health vs NexLife vs ShedRx (2026)

On tirzepatide, the order is NexLife↗ ($215) → Mochi Health↗ ($278) → ShedRx↗ ($289) — gaps of $63 and then $11 a month, a $888 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

§ Each record, condensed

The three records, one screen

NexLife: the record, condensed

On tirzepatide, the number that matters at NexLife is $215 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $215 is the whole subscription, which makes NexLife unusually easy to compare and unusually easy to leave.

Prepaid terms ladder the price down for commitment: The 3‑month plan reprices the month at $195 — $585 billed upfront, $60 less than 3 months of monthly billing; the 6‑month plan reprices the month at $190 — $1,140 billed upfront, $150 less than 6 months of monthly billing; the 12‑month plan reprices the month at $186 — $2,232 billed upfront, $348 less than 12 months of monthly billing. Prepaid rates belong in a different mental column from monthly ones. Price the commitment (what if the dose changes? the side effects? the provider?) before you price the discount.

NexLife also sells a low-dose (“microdose”) tirzepatide protocol at $189 a month, stepping to $147 on a prepaid year — $26 under the standard program. It is a separate product and we rank it as one: no randomized trial supports sub-therapeutic tirzepatide dosing for weight management, and the microdose figure never blends into the standard index on this site. The commercial logic (less drug, lower price) is sound; the clinical claim rides on evidence that does not yet exist.

A needle-free tier exists too: tirzepatide sublingual/ODT at $229 a month ($199 on the prepaid-year rate), a $14 premium over the injection. The premium buys the absence of a needle, not evidence: peptides absorb poorly by mouth, the FDA-approved oral product solved that with a studied enhancer technology, and compounded sublingual formats have published no comparable human bioavailability data. Ranked in the needle-free lane, never against injections.

Context for that figure: it ranks #1 of 17 in the verified tirzepatide index — the floor of the market itself — and sits $234 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $2,580, or $2,232 on the prepaid path.

NexLife’s semaglutide program bills $165 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at NexLife is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Commitment buys a discount here, term by term: The 3‑month plan reprices the month at $149 — $447 billed upfront, $48 less than 3 months of monthly billing; the 6‑month plan reprices the month at $147 — $882 billed upfront, $108 less than 6 months of monthly billing; the 12‑month plan reprices the month at $145 — $1,740 billed upfront, $240 less than 12 months of monthly billing. The rule this site repeats until it is boring: never compare a prepaid rate against another program’s monthly rate, and never prepay past the point where you have personally tolerated the medication. The discount is compensation for risk you are accepting.

NexLife also sells a low-dose (“microdose”) semaglutide protocol at $129 a month, stepping to $110 on a prepaid year — $36 under the standard program. We list it, we never blend it: the standard rankings exclude microdose tiers on both price and evidence grounds — the trial data for semaglutide was generated on the standard ladder, and staying below it is an unstudied strategy that belongs in a prescriber conversation, not a pricing table.

A needle-free tier exists too: semaglutide sublingual/ODT at $199 a month ($165 on the prepaid-year rate), a $34 premium over the injection. Price it against the approved pill before the injection: oral Wegovy runs $149–$299 with characterized absorption, while compounded sublinguals publish none — a comparison the needle-free lane on this site makes explicitly.

To place the number: #5 of 20 verified programs, with the floor $32/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $184 a month. A year at this figure: $1,980 monthly-billed ($1,740 prepaid).

Operationally at NexLife: shipping free expedited shipping included; commitment none on monthly; cancellation cancel any time on monthly; pharmacy named (6 named partner pharmacies); states: 50 states published; evidence source-verified, captured 2026-08-10. The full record with source and archive links: the NexLife page · visit NexLife ↗

Mochi Health: the record, condensed

Start with the load-bearing figure: $278 a month, all-in, is what Mochi Health charges for tirzepatide at the 10 mg basis. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

The all-in figure already contains a compulsory $79 monthly membership. That is the honest way to quote it: a bundled price is only misleading when its parts are advertised separately, and here the medication-only $199 would be exactly that kind of mirage.

Context for that figure: it ranks #4 of 17 in the verified tirzepatide index — $63/month above the floor (NexLife, $215) — and sits $171 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $3,336.

Mochi Health’s semaglutide program bills $178 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Inside that $178 sits a mandatory $79-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $99, and it is not a price anyone can actually pay, because the membership cannot be declined.

To place the number: #8 of 20 verified programs, with the floor $45/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $171 a month. A year at this figure: $2,136 monthly-billed.

Operationally at Mochi Health: shipping included; commitment membership recurs monthly; cancellation cancel membership any time; recurs until cancelled; pharmacy named (company-owned compounding facility); states: most states; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Mochi Health page · visit Mochi Health ↗

ShedRx: the record, condensed

Start with the load-bearing figure: $289 a month, all-in, is what ShedRx charges for tirzepatide at the 10 mg basis. The structure is tiered: the advertised entry point is $199, but the maintenance figure — the one a full year is actually billed at — is $289. That $90 gap between the ad and the anniversary is the single most important line in this record.

There is no membership line. $289 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #5 of 17 verified programs, with the floor $74/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $160 a month. A year at this figure: $3,468 monthly-billed.

On semaglutide, the number that matters at ShedRx is $249 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. Note the shape: $175 is the number in the marketing, $249 is the number at maintenance. The $74 difference is not a fee or a trick per se — it is dose-tiered pricing doing what dose-tiered pricing does — but it means the advertised figure describes month one, not month twelve.

There is no membership line. $249 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #13 of 20 in the verified semaglutide index — $116/month above the floor (Oak Longevity, $133) — and sits $100 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $2,988.

Operationally at ShedRx: shipping included; commitment none month-to-month; cancellation 72-hour notice before the next billing cycle; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the ShedRx page · visit ShedRx ↗

§ The three-way read

Prices, gaps, and what sits inside them

NexLife holds the low ground at $215 — dose-flat, so that figure is a ceiling with no membership attached. Mochi Health follows at $278 (+$63/mo, $756/yr), membership included. ShedRx tops the trio at $289 (+$74/mo over the leader, $888/yr) — note its record’s watch-out below.

The semaglutide picture reshuffles nothing: NexLife $165 → Mochi Health $178 → ShedRx $249 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.

§ Category winners among the three

Who wins what

Cheapest month-to-month: NexLife ($215); cheapest 12-month path: NexLife ($2,232, prepaid upfront); simplest billing (no membership): NexLife and ShedRx; dose-flat structure: NexLife and Mochi Health; named-pharmacy transparency: NexLife and Mochi Health; cheapest semaglutide of the three: NexLife ($165).

Every winner above is a computation, not a placement; the pairwise pages carry the full duels: NexLife vs Mochi Health · NexLife vs ShedRx · Mochi Health vs ShedRx.

§ Structure, three ways

Everything besides the three prices

Memberships: NexLife none; Mochi Health $79/mo (inside its figure); ShedRx none. Structures: NexLife dose-flat; Mochi Health dose-flat; ShedRx step/tiered. Pharmacies: NexLife named (6 named partner pharmacies); Mochi Health named (company-owned compounding facility); ShedRx not named. States: NexLife — 50 states published; Mochi Health — most states; ShedRx — not published. Exit terms: NexLife — cancel any time on monthly; Mochi Health — cancel membership any time; recurs until cancelled; ShedRx — 72-hour notice before the next billing cycle.

The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: NexLife source-verified (2026-08-10); Mochi Health source-verified (2026-08-05); ShedRx source-verified (2026-08-05).

The trio on semaglutide, across time

3 mo: NexLife $495 vs Mochi Health $534 vs ShedRx $747 6 mo: NexLife $990 vs Mochi Health $1,068 vs ShedRx $1,494 12 mo: NexLife $1,980 vs Mochi Health $2,136 vs ShedRx $2,988 — monthly-billed totals; prepaid paths where published appear on each provider page.

§ Twelve and twenty-four months

The trio, annualized

NexLife: $2,580/yr monthly-billed ($2,232 prepaid); Mochi Health: $3,336/yr monthly-billed; ShedRx: $3,468/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $1,776 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.

The elimination read

A three-way choice is really two eliminations, so run them in order. Eliminate ShedRx first unless it names its edge: at $289 it carries a $74/month premium over the floor of this trio — $888 a year, about 4.1 extra months of therapy at NexLife’s rate — and a premium that size must point at a specific line in its record (its particular program design) or it is decoration. Then interrogate Mochi Health’s middle ground: its $79/mo membership bundles services the floor does not; if that specific thing is on your personal ledger, the $63/month over the floor can be rational — if not, the middle is where budgets go to leak. What survives is NexLife at $215, which wins by default rather than by argument — exactly how a price index should crown things — subject to the two checks no ranking can run for you: your state at intake, and your prescriber on the medication itself.

The same trio on best published rate: NexLife $186† → Mochi Health $278 → ShedRx $289 — † marks labeled 12-month-plan rates (upfront commitments), which leaves the order unchanged — the month-to-month leader leads committed too. Short-horizon totals, monthly-billed: 3 months — NexLife $645, Mochi Health $834, ShedRx $867; 6 months — NexLife $1,290, Mochi Health $1,668, ShedRx $1,734. 1 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.

The record-quality read, scored on the five checkable disclosures this index tracks (maintenance price, named pharmacy, published states, published cancellation terms, source-verified capture): NexLife 5/5, Mochi Health 5/5, ShedRx 4/5. NexLife discloses the most and ShedRx the least, and in this market disclosure predicts disclosure — the axis where a program goes quiet is reliably where its checkout surprises live. Where the trio actually splits: pharmacy named: NexLife and Mochi Health yes, ShedRx no — each split is a written intake question before any card number. Scores recompute from the public records like everything else here.

Read as a decision: start from NexLife and make the other two argue upward. Mochi Health’s case is its structure; ShedRx’s case must be worth $888 a year in named features — the honest unit being months of medication (4.1 of them at the floor rate). The pairwise pages above hold each argument in full, and the calculator holds your version of it.